FDMT. – 4D Molecular Therapeutics Inc
Float Short %
20.21
Margin Of Safety %
Put/Call OI Ratio
0.13
EPS Next Q Diff
-1.62
EPS Last/This Y
-0.28
EPS This/Next Y
-0.22
Price
9.02
Target Price
33.11
Analyst Recom
1.45
Performance Q
-10.6
Upside
-667.8%
Beta
2.99
Ticker: FDMT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | FDMT | 7.96 | 0.12 | 0.88 | 2601 |
| 2026-01-26 | FDMT | 7.97 | 0.13 | 0.14 | 2628 |
| 2026-01-27 | FDMT | 8.51 | 0.13 | 0.00 | 2631 |
| 2026-01-28 | FDMT | 8.61 | 0.11 | 0.03 | 2936 |
| 2026-01-29 | FDMT | 8.97 | 0.11 | 0.00 | 2964 |
| 2026-01-30 | FDMT | 8.86 | 0.11 | 3.00 | 3024 |
| 2026-02-02 | FDMT | 9.17 | 0.11 | 0.15 | 3026 |
| 2026-02-03 | FDMT | 9.5 | 0.11 | 0.91 | 3258 |
| 2026-02-04 | FDMT | 9.31 | 0.12 | 0.39 | 3279 |
| 2026-02-05 | FDMT | 8.4 | 0.12 | 2.86 | 3314 |
| 2026-02-06 | FDMT | 8.96 | 0.13 | 0.00 | 3339 |
| 2026-02-09 | FDMT | 9.08 | 0.13 | 0.00 | 3339 |
| 2026-02-10 | FDMT | 9.12 | 0.12 | 0.77 | 3438 |
| 2026-02-11 | FDMT | 9.25 | 0.12 | 0.77 | 3438 |
| 2026-02-12 | FDMT | 9.28 | 0.13 | 0.00 | 3450 |
| 2026-02-13 | FDMT | 9.35 | 0.13 | 0.34 | 3460 |
| 2026-02-17 | FDMT | 9.47 | 0.13 | 0.00 | 3467 |
| 2026-02-18 | FDMT | 9.18 | 0.13 | 0.00 | 3468 |
| 2026-02-20 | FDMT | 9.01 | 0.13 | 1.20 | 3479 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | FDMT | 7.97 | 41.3 | - | -3.26 |
| 2026-01-26 | FDMT | 7.97 | 41.3 | - | -3.26 |
| 2026-01-27 | FDMT | 8.51 | 41.3 | - | -3.26 |
| 2026-01-28 | FDMT | 8.57 | 41.3 | - | -3.26 |
| 2026-01-29 | FDMT | 8.98 | 41.3 | - | -3.26 |
| 2026-01-30 | FDMT | 8.86 | 41.3 | - | -3.26 |
| 2026-02-02 | FDMT | 9.14 | 41.3 | - | -3.26 |
| 2026-02-03 | FDMT | 9.49 | 41.3 | - | -3.26 |
| 2026-02-04 | FDMT | 9.31 | 41.3 | - | -3.26 |
| 2026-02-05 | FDMT | 8.39 | 41.3 | - | -3.26 |
| 2026-02-06 | FDMT | 8.98 | 41.3 | - | -3.26 |
| 2026-02-09 | FDMT | 9.08 | 41.3 | - | -3.26 |
| 2026-02-10 | FDMT | 9.13 | 41.3 | - | -3.26 |
| 2026-02-11 | FDMT | 9.24 | 41.3 | - | -3.26 |
| 2026-02-12 | FDMT | 9.38 | 41.3 | - | -3.26 |
| 2026-02-13 | FDMT | 9.35 | 41.3 | - | -3.26 |
| 2026-02-17 | FDMT | 9.48 | 41.3 | - | -3.26 |
| 2026-02-18 | FDMT | 9.17 | 41.3 | - | -3.26 |
| 2026-02-19 | FDMT | 9.16 | 41.3 | - | -3.26 |
| 2026-02-20 | FDMT | 9.02 | 41.3 | - | -3.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | FDMT | -0.25 | -2.05 | 17.30 |
| 2026-01-26 | FDMT | -0.25 | -2.00 | 16.68 |
| 2026-01-27 | FDMT | -0.25 | -2.00 | 16.68 |
| 2026-01-28 | FDMT | -0.25 | -2.00 | 18.23 |
| 2026-01-29 | FDMT | -0.28 | -2.00 | 18.23 |
| 2026-01-30 | FDMT | -0.28 | -2.00 | 18.23 |
| 2026-02-02 | FDMT | -0.28 | -2.59 | 18.23 |
| 2026-02-03 | FDMT | -0.28 | -2.59 | 18.23 |
| 2026-02-04 | FDMT | -0.28 | -2.59 | 18.23 |
| 2026-02-05 | FDMT | -0.28 | -2.59 | 18.23 |
| 2026-02-06 | FDMT | -0.28 | -2.59 | 20.42 |
| 2026-02-10 | FDMT | -0.28 | -0.88 | 20.42 |
| 2026-02-11 | FDMT | -0.28 | -0.88 | 19.99 |
| 2026-02-12 | FDMT | -0.28 | -0.88 | 19.99 |
| 2026-02-13 | FDMT | -0.28 | -0.88 | 19.99 |
| 2026-02-17 | FDMT | -0.25 | 2.94 | 20.21 |
| 2026-02-18 | FDMT | -0.25 | 2.94 | 20.21 |
| 2026-02-19 | FDMT | -0.25 | 2.94 | 20.21 |
| 2026-02-20 | FDMT | -0.25 | 2.94 | 20.21 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.69
Avg. EPS Est. Current Quarter
-0.53
Avg. EPS Est. Next Quarter
-0.93
Insider Transactions
-0.25
Institutional Transactions
2.94
Beta
2.99
Average Sales Estimate Current Quarter
30
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
17
Growth Score
26
Sentiment Score
63
Actual DrawDown %
83.6
Max Drawdown 5-Year %
-95.1
Target Price
33.11
P/E
Forward P/E
PEG
P/S
3834.07
P/B
1.14
P/Free Cash Flow
EPS
-3.94
Average EPS Est. Cur. Y
-3.26
EPS Next Y. (Est.)
-3.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-174314.17
Relative Volume
0.73
Return on Equity vs Sector %
-85.7
Return on Equity vs Industry %
-68.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
4D Molecular Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading